MONITOR: The coadministration with methylphenidate may increase the plasma concentrations of selective serotonin reuptake inhibitors (SSRIs). According to the manufacturer, human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of SSRIs, and there have been reports that methylphenidate augments the clinical response to SSRIs.
MANAGEMENT: Pharmacologic response to SSRIs should be monitored more closely whenever methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is added to or withdrawn from therapy, and the SSRI dosage adjusted as necessary.
However, please do seek medical advice from the doc/pharmacist who prescribed the meds. Take care!
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Posted 20 Jul 2011 • 2 answers
Posted 20 Dec 2013 • 1 answer
Posted 1 Nov 2014 • 1 answer
Posted 21 Jan 2016 • 1 answer
Posted 29 Dec 2016 • 1 answer